Answers are grounded in this paper and cite their sources.
In summary, patients with GT and history of severe hemorrhage can be cured with BMT, but the presence of anti-platelet antibodies should be sought and platelet transfusions minimized prior to transplant. IVIG may be helpful in cases of refractory immune thrombocytopenia related to anti-platelet antibodies. Improvement in transplant-related complications with current transplant regimens allows consideration of BMT for life-threatening non-malignant disorders such as GT.
No takes yet. Share an insight, caveat, or question.
Flood et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: